NATCO Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NATCO Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 14% of its market value (net cash). Higher than 95% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹52 became extra profit. Higher than 92% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 3.7 times. Higher than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹100Over the last 3 years, every ₹100 of reported profit came with ₹100 of operating cash.
Lower than 53% of Healthcare companies in India.
Self-Funding Ratio
3.7×Over the last 3 years its own operating cash covered its investment spending (capex) 3.7 times.
Higher than 85% of Healthcare companies in India.
Cash Locked Ratio
₹32For every ₹100 of sales, ₹32 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier.
More money tied up than 66% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹52Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹52 became extra profit.
Higher than 92% of Healthcare companies in India.
Asset Productivity Ratio
+50% / +96%In 3 years sales changed by +50% while total assets changed by +96%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.9×Debt due within a year is covered 2.9 times by its yearly operating cash.
Higher than 64% of Healthcare companies in India.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 95% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 52% of Healthcare companies in India.
Tangible Net Worth Ratio
97%Of every ₹100 of net worth, ₹97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 53% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
NATCO Pharma Limited owes ₹0.17 for every ₹1 it owns. Net profit fell 25% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
12.4Investors pay ₹12.4 for every ₹1 of NATCO Pharma Limited's yearly profit, lower than 92% of Healthcare companies in India.
P/B ratio
1.57The share price is 1.57 times NATCO Pharma Limited's book value per share, lower than 93% of Healthcare companies in India.
Market cap
₹14,447 CrThe total market value of all of NATCO Pharma Limited's shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹9,221 CrWhat NATCO Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹501.15Net worth divided by the number of shares. The share price of ₹785.15 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
12.3%NATCO Pharma Limited earned 12.3% on its shareholders' money over the last year, lower than 53% of Healthcare companies in India.
Owes vs Owns
0.17×NATCO Pharma Limited owes ₹0.17 for every ₹1 it owns (low), lower than 89% of Healthcare companies in India.
Dividend yield
0.75%NATCO Pharma Limited pays 0.75% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in India.
Revenue growth
-8%Revenue fell 8% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit growth
-25%Net profit fell 25% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Profit margin
35.1%NATCO Pharma Limited keeps ₹35 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from NATCO Pharma Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
48.7×NATCO Pharma Limited's operating profit covered its interest costs 48.7 times in the year to Mar 2026.
Cash vs debt
Net cashNATCO Pharma Limited held ₹2,074 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is NATCO Pharma Limited's P/E ratio?
Investors pay ₹12.4 for every ₹1 of NATCO Pharma Limited's yearly profit, lower than 92% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NATCO Pharma Limited: ₹14,447 Cr ÷ ₹9,221 Cr (31 Mar 2026) = 1.6.
What is NATCO Pharma Limited's return on equity?
NATCO Pharma Limited earned 12.3% on its shareholders' money over the last year, lower than 53% of Healthcare companies in India.
How much does NATCO Pharma Limited owe compared with what it owns?
NATCO Pharma Limited owes ₹0.17 for every ₹1 it owns (low), lower than 89% of Healthcare companies in India.
Does NATCO Pharma Limited pay a dividend?
Yes. NATCO Pharma Limited pays 0.75% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in India.
Is NATCO Pharma Limited's revenue growing?
Revenue fell 8% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.